NYSEConsumer StaplesHousehold & Personal ProductsSnapshot 2026-08-31
Reading CL? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
Colgate-Palmolive grows revenue about 4.4% yearly as analysts expect. Profit margins remain stable despite some pressure. The company executes a productivity program to support growth. Free cash flow yield is steady at 5%.
Revenue growth could slow below 2% if productivity gains lag. Margins may compress further given lowered gross margin guidance. The CEO transition creates some uncertainty in management execution.
The price is about 8% above our fair value near $88, reflecting roughly 4% revenue growth. Our fair value is 10% below the Street median, indicating some caution versus consensus.
Breaks if: Program progress stalls or reverses over next year
Breaks if: Gross margin falls significantly below mid-cycle levels
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on steady revenue growth and strategic initiatives. The current thesis state is intact, supported by strong recent financial performance.
The market appears to be pricing in a low level of fragility, with expectations for continued performance in the top half of the industry. The valuation reflects a durable premium compared to peers, indicating that some growth is already anticipated.
Fundamentals are likely to remain stable, given the recent strong financial results and management's commitment to growth initiatives. However, there is a moderate risk due to potential economic headwinds that could impact performance.
The long-term thesis hinges on management's ability to execute its strategic growth initiatives and navigate economic challenges. Key factors include the potential impact of inflation and any changes in guidance that could affect credibility.
The most important moves since the prior daily snapshot.
Our read has strengthened. It is supported by the latest earnings beat.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: YoY revenue growth falls below 2% in FY26
Overall, CL is positioned well but must manage risks effectively to maintain its trajectory. Not investment advice.
